Immunotherapy News and Research

Latest Immunotherapy News and Research

DNA sequencing can direct immune system to attack cancer

DNA sequences from tumor cells can be used to direct the immune system to attack cancer, according to scientists at Washington University School of Medicine in St. Louis.

9 Feb 2012

Elan fourth quarter total revenue increases 18% to $271.0 million

Elan Corporation, plc today reported its fourth quarter and full-year 2011 financial results.

8 Feb 2012

New immunotherapy combination prolongs survival in dogs with NHL

A new immunotherapy for companion dogs with advanced-stage non-Hodgkin lymphoma (NHL) has been shown to improve survival while maintaining quality of life, according to a study published in the journal Scientific Reports.

8 Feb 2012

Clinical Cancer Research publishes results of Aduro's ANZ-100 and CRS-207 Phase 1 studies

Aduro BioTech, Inc. is pleased to announce the publication of two therapeutic cancer vaccine Phase 1 studies in Clinical Cancer Research. In the article, which was featured as one of the highlights of the issue, Dr. Dung Le et al. reported that intravenous administration of ANZ-100 and CRS-207 was well tolerated in subjects with advanced, treatment-refractory cancers.

7 Feb 2012

Immune cells from healthy individuals effectively kill cancer cells

Immune cells from healthy individuals can be the new immune cure for cancer. This treatment can kill cancer cells without destroying neighbouring cells. The hope is to eradicate cancer for ever.

3 Feb 2012

Blood cell therapy works for nasopharyngeal cancer: Study

Scientists from the Queensland Institute of Medical Research have made a breakthrough in the treatment of throat cancer. The researchers have developed a therapy that uses a patient's blood to grow special white blood cells that recognize and fight infected cancer cells. The results of this study have been published in the journal Cancer Research.

2 Feb 2012

Abnormal tau protein propagates along linked brain circuits

For decades, researchers have debated whether Alzheimer's disease starts independently in vulnerable brain regions at different times, or if it begins in one region and then spreads to neuroanatomically connected areas. A new study by Columbia University Medical Center (CUMC) researchers strongly supports the latter, demonstrating that abnormal tau protein, a key feature of the neurofibrillary tangles seen in the brains of those with Alzheimer's, propagates along linked brain circuits, "jumping" from neuron to neuron.

2 Feb 2012

Scientists identify TDO enzyme as new target for cancer therapy

Scientists from the Ludwig Institute for Cancer Research (LICR) in Brussels identified a new target for cancer therapy, an enzyme which prevents the immune system from recognizing and destroying certain types of tumors.

1 Feb 2012

IMUC president to present at Immunotherapeutics Partnering and Deal Making Conference

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012.

31 Jan 2012

Anti-HER2 dendritic cell vaccine shows promise against DCIS

Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient's own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ (DCIS), an early breast cancer.

31 Jan 2012

Novo Nordisk Type 1 Diabetes R&D Center to be established in Seattle

Novo Nordisk announced today that the company will establish a type 1 diabetes research and development center in Seattle, Wash., U.S. The new center will combine Novo Nordisk's history of innovation and leadership in diabetes treatment with the company's growing expertise in immunotherapy.

24 Jan 2012

Cedars-Sinai's annual Brainworks program to take place on Feb. 13

Taking turns gazing into a surgical microscope, 130 seventh- and eighth-graders from Los Angeles area schools will see a phantom skull and perform virtual surgery - and many could catch a glimpse of the future.

20 Jan 2012

New path for individually tailored cancer therapy

The Institute of Translational Oncology (TRON) together with BioNTech AG today announced the publication of a joint paper in the international journal Cancer Research that describes a new path for individually tailored cancer therapy.

18 Jan 2012

Mentor executes long-term funding agreement to receive 50% ownership in Brighter Day Health

Mentor Capital, Inc. announced that it has executed a long-term funding agreement to receive a current 50% ownership in Brighter Day Health, LLC, pending their expected shareholder approval.

17 Jan 2012

Stallergenes chooses Magic Software's iBOLT integration platform

Magic Software Enterprises Ltd., a global provider of mobile and cloud-enabled application and business integration platforms, announced today that Stallergenes, a biopharmaceutical company and world leader in the treatment of severe allergic respiratory illnesses, has chosen Magic Software's iBOLT integration platform to integrate its various purchasing systems with its SAP ERP.

17 Jan 2012

Bladder cancer is one of the top 10 most common forms of cancer in the US

Bladder cancer, most frequently caused by smoking and exposure to carcinogens in the workplace, is one of the top 10 most common forms of cancer in men and women in the U.S. More than 70 percent of bladder cancers are diagnosed in stage T1 or less and have not invaded the muscle layer.

11 Jan 2012

Celldex begins rindopepimut and Avastin Phase 2 combination trial in EGFRvIII-positive GB

Celldex Therapeutics, Inc. today announced that patient screening has initiated in a Phase 2 trial of rindopepimut in combination with Avastin in patients with recurrent epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, called the "ReACT Study."

5 Jan 2012

Antigen Express to move AE37 cancer vaccine into larger clinical trials

Generex Biotechnology Corporation today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.

4 Jan 2012

CSF Aβ42 levels appear to be decreased before patients with MCI develop AD dementia

Cerebrospinal fluid levels of Aβ42 appear to be decreased at least five to 10 years before some patients with mild cognitive impairment develop Alzheimer disease (AD) dementia whereas other spinal fluid levels seem to be later markers of disease, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

2 Jan 2012

Additional financing to fund Advaxis' cervical cancer trials

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has entered into a definitive Convertible Notes Purchase Agreement (Agreement) with certain accredited investors, for the purchase of the aggregate principal value of approximately $1.2 million of Convertible Promissory Notes (Notes) for an aggregate purchase price of approximately $1.0 million.

31 Dec 2011

Immunotherapy News and Research

Latest Immunotherapy News and Research

DNA sequencing can direct immune system to attack cancer

Elan fourth quarter total revenue increases 18% to $271.0 million

New immunotherapy combination prolongs survival in dogs with NHL

Clinical Cancer Research publishes results of Aduro's ANZ-100 and CRS-207 Phase 1 studies

Immune cells from healthy individuals effectively kill cancer cells

Blood cell therapy works for nasopharyngeal cancer: Study

Abnormal tau protein propagates along linked brain circuits

Scientists identify TDO enzyme as new target for cancer therapy

IMUC president to present at Immunotherapeutics Partnering and Deal Making Conference

Anti-HER2 dendritic cell vaccine shows promise against DCIS

Novo Nordisk Type 1 Diabetes R&D Center to be established in Seattle

Cedars-Sinai's annual Brainworks program to take place on Feb. 13

New path for individually tailored cancer therapy

Mentor executes long-term funding agreement to receive 50% ownership in Brighter Day Health

Stallergenes chooses Magic Software's iBOLT integration platform

Bladder cancer is one of the top 10 most common forms of cancer in the US

Celldex begins rindopepimut and Avastin Phase 2 combination trial in EGFRvIII-positive GB

Antigen Express to move AE37 cancer vaccine into larger clinical trials

CSF Aβ42 levels appear to be decreased before patients with MCI develop AD dementia

Additional financing to fund Advaxis' cervical cancer trials

eBook: The Ultimate Guide to Successful Immunofluorescence eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: The Ultimate Guide to Successful Immunofluorescence eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in